Reinhard von Roemeling
Directeur Technique/Scientifique/R&D chez CURIS, INC.
Profil
Reinhard von Roemeling is currently the Senior Vice President-Clinical Development at Curis, Inc. He was previously the Global Head-Research & Development at HUYA Bioscience International LLC.
Dr. von Roemeling holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Postes actifs de Reinhard von Roemeling
Sociétés | Poste | Début |
---|---|---|
CURIS, INC. | Directeur Technique/Scientifique/R&D | 13/08/2019 |
Anciens postes connus de Reinhard von Roemeling
Sociétés | Poste | Fin |
---|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Reinhard von Roemeling
Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
CURIS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |